Chugai Pharmaceutical Co., Ltd. has launched atezolizumab, a recombinant humanized anti-PD-L1 monoclonal antibody, (Tecentriq Intravenous Infusion 1200 mg) for the treatment of “unresectable advanced or recurrent non-small cell lung cancer (NSCLC).
Tecentriq received a manufacturing and marketing approval on January 19, 2018 and was listed on the National Health Insurance (NHI) reimbursement price list.
“Cancer immunotherapy is expected to be a breakthrough therapy which may significantly change cancer treatment. As our mission is to deliver innovative therapeutic drugs to patients, it is a great pleasure for us to finally being able to launch Tecentriq,” said Chugai’s president & CEO, Tatsuro Kosaka. “We will continue our research and development activities in multiple cancer types and combination therapies to realize sustained therapeutic effects and improvement of survival rate, as well as cure in more patients with cancer.”
Tecentriq is an immune checkpoint inhibitor targeting PD-L1 (Programmed Death-Ligand 1) which is a protein expressed on tumour cells and tumour-infiltrating immune cells. PD-L1 blocks T-cell activity by binding with PD-1 and B7.1 receptors on T-cell surface. By inhibiting PD-L1, Tecentriq may enable the activation of T-cells and boost immune response against cancer cells.
In Japan, the annual prevalence of lung cancer is estimated to be approximately 128,700 in 2017 (male: 86,700, female: 42,000). The annual mortality of lung cancer, the leading cause of cancer deaths (the second leading cause in women) in Japan, is approximately 78,000 (male: 55,600, female: 22,400; predicted figure for 2017).
As a top company in the field of oncology in Japan, Chugai firmly believes that the launch of Tecentriq in Japan as a new therapeutic option for the treatment of “unresectable advanced or recurrent NSCLC,” will allow us to further contribute to treat patients and promote appropriate use of drugs.